Can I Take Folate with Retatrutide?

What Retatrutide Is and Why It Matters for Nutritional Status

Retatrutide is a once-weekly subcutaneous peptide that acts simultaneously on glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. The Phase 2 RETATRUTIDE trial (NCT05019261, N=338) published in the New England Journal of Medicine in 2023 showed mean body-weight reduction of 17.5% at 24 weeks on the 12 mg dose versus 1.6% on placebo [1]. That magnitude of weight loss is large enough to affect dietary intake patterns, absorption kinetics, and micronutrient status.

How GLP-1-Class Drugs Affect Nutrient Absorption

GLP-1 receptor agonists slow gastric emptying, which can reduce the rate of oral nutrient absorption without necessarily reducing the total amount absorbed [2]. For most water-soluble vitamins, including folate, slower gastric transit does not cause clinically meaningful depletion in otherwise healthy adults eating a balanced diet. The concern arises when a patient is already restricting calories, eating a narrow range of foods, or has pre-existing micronutrient insufficiency.

Why Folate Specifically Comes Up

Folate is a B-vitamin required for one-carbon metabolism, DNA synthesis, and homocysteine remethylation [3]. Patients losing significant weight on any therapy, retatrutide included, often reduce total food intake and may inadvertently cut folate-rich foods such as leafy greens and legumes. Some patients co-prescribe retatrutide with medications that deplete folate, most notably metformin (used for type 2 diabetes or PCOS) and anticonvulsants such as valproate or phenytoin [4].

Pharmacokinetic Interaction Profile: Retatrutide and Folate

No pharmacokinetic drug-supplement interaction between retatrutide and folate has been identified in the published literature as of January 2025. This is the expected finding given the distinct mechanisms involved.

Retatrutide Pharmacokinetics

Retatrutide is a fatty-acid-conjugated peptide with a half-life of approximately 6 days, enabling once-weekly dosing [1]. It is not metabolized by cytochrome P450 enzymes and is not a substrate or inhibitor of the major drug transporters (P-gp, BCRP, OATP). Folate absorption relies on proton-coupled folate transporter (PCFT) and reduced folate carrier (RFC) in the small intestine, pathways entirely separate from retatrutide's receptor targets [3].

Folate Pharmacokinetics

Dietary folate polyglutamates are hydrolyzed to monoglutamates before intestinal absorption. The synthetic form, folic acid, is absorbed with approximately 85% bioavailability when taken with food and nearly 100% on an empty stomach [3]. Once absorbed, folic acid is converted to 5-methyltetrahydrofolate (5-MTHF) in the liver, the form that circulates and enters cells. L-methylfolate supplements bypass this conversion step entirely, which matters for MTHFR variant carriers (see below).

The Indirect Interaction: Nausea and Reduced Supplement Adherence

The realistic interaction between retatrutide and folate is behavioral rather than biochemical. Retatrutide at 12 mg produced nausea in 42% of participants in the Phase 2 trial [1]. Nausea can reduce a patient's willingness to swallow multiple supplements daily and may cause vomiting that reduces absorption of a recently taken pill. Taking folate with food, or switching from folic acid to L-methylfolate (which tends to cause less GI irritation for some patients), can address this practical barrier.

MTHFR Variants and Retatrutide Patients

MTHFR C677T and A1298C polymorphisms reduce the enzyme's ability to convert folic acid to the active 5-MTHF form. Approximately 10 to 15% of the general U.S. Population carries two copies of the C677T variant (homozygous), resulting in enzyme activity as low as 30% of normal [5].

Why MTHFR Matters More on a Calorie-Restricted Regimen

Patients homozygous for MTHFR C677T may have elevated plasma homocysteine even at normal serum folate levels because the conversion bottleneck limits the remethylation of homocysteine to methionine [5]. When caloric restriction further lowers dietary folate intake, this risk compounds. A 2012 meta-analysis in The Lancet (N=37,914 pooled from 8 trials) found that B-vitamin supplementation including folate reduced plasma homocysteine by approximately 25%, though cardiovascular event reduction was modest in populations without pre-existing deficiency [6].

Recommended Form for MTHFR Carriers

For patients with confirmed MTHFR C677T homozygosity, L-methylfolate (5-MTHF) at 400 to 1,000 mcg daily is preferred over standard folic acid because it bypasses the impaired enzymatic step [5]. The HealthRX medical team recommends testing for MTHFR status in any retatrutide patient who presents with elevated homocysteine (>15 µmol/L) or a personal or family history of neural tube defects, recurrent pregnancy loss, or cardiovascular disease at young age.

Folate Requirements on Retatrutide: Dose Guidance by Patient Type

Standard dietary reference intakes from the NIH Office of Dietary Supplements set the Recommended Dietary Allowance (RDA) for folate at 400 mcg of dietary folate equivalents (DFE) per day for adults, rising to 600 mcg DFE during pregnancy [7]. These values do not change because a patient is taking retatrutide. The retatrutide context changes only the probability that a patient will meet those targets through diet alone.

Standard Adult Patients

Most adults taking retatrutide for weight management who eat a varied diet, even a calorie-restricted one, can meet folate requirements with a standard multivitamin containing 400 to 800 mcg folic acid. No dose adjustment or separation window from retatrutide injection is needed. Retatrutide is injected subcutaneously once weekly; oral folate is absorbed through an entirely separate route.

Patients on Metformin

Metformin reduces serum B12 and may reduce folate through competitive inhibition of intestinal absorption, though the folate effect is less consistently documented than the B12 effect [4]. A 2006 Annals of Internal Medicine report noted that long-term metformin use (median 4.3 years) lowered serum folate by a statistically significant margin in patients with type 2 diabetes [4]. Retatrutide is being studied in patients with obesity-related type 2 diabetes, meaning metformin co-use is common in this population. These patients should receive at minimum 800 mcg folic acid or 400 to 1,000 mcg L-methylfolate daily and have folate and B12 monitored annually.

Patients on Anticonvulsants

Valproate, phenytoin, carbamazepine, and phenobarbital all reduce serum folate through different mechanisms: enzyme induction accelerates folate catabolism, and valproate directly inhibits folate-dependent enzymes [8]. Patients taking these anticonvulsants alongside retatrutide may need 1,000 to 5,000 mcg folic acid daily under physician supervision, per guidance from the American Academy of Neurology and the Epilepsy Foundation. Serum folate and homocysteine should be checked at baseline and every 6 months in this group [8].

Women of Childbearing Potential

GLP-1-class drugs including retatrutide are not approved for use in pregnancy. The FDA label for semaglutide (a structurally related GLP-1 agonist, though retatrutide is still investigational) recommends discontinuation at least 2 months before planned conception given the long half-life and animal reproductive toxicity data [9]. Women who might become pregnant while on retatrutide should take at least 400 to 800 mcg folate daily as neural-tube-defect prophylaxis, consistent with USPSTF Grade B recommendation [10], and should have a clear plan to discontinue retatrutide and confirm adequate folate status before conception.

Monitoring Protocol When Taking Folate and Retatrutide Together

Routine monitoring supports both safety and efficacy. The following schedule reflects standard clinical practice for patients on investigational weight-management peptides combined with micronutrient supplementation.

Baseline Labs

Before starting retatrutide (or at the first visit if already on it), obtain serum folate, red blood cell (RBC) folate, vitamin B12, and homocysteine. RBC folate reflects tissue stores over the preceding 2 to 3 months and is a more stable marker than serum folate, which fluctuates with recent dietary intake [7]. If homocysteine exceeds 15 µmol/L, consider MTHFR genotyping or empirically switch to L-methylfolate.

Follow-Up Labs

Repeat serum or RBC folate and homocysteine at 3 months after starting retatrutide (coinciding with the dose-escalation period when nausea peaks and dietary intake may be most restricted) and then every 6 to 12 months. The dose-escalation schedule in the Phase 2 trial ramped from 1 mg to 12 mg over 24 weeks [1], meaning the highest nausea burden occurs in the first 3 to 4 months.

When to Escalate Folate Dose

If serum folate falls below 3 ng/mL or homocysteine rises above 15 µmol/L during retatrutide therapy, increase folate supplementation to 800 to 1,000 mcg daily and recheck in 8 weeks. A persistent elevation in homocysteine despite adequate folate supplementation warrants addition of methylcobalamin (B12) 500 to 1,000 mcg daily and pyridoxine (B6) 25 to 50 mg daily, since all three B-vitamins participate in homocysteine metabolism [6].

Folate and Retatrutide's Glucagon Component: An Emerging Consideration

Retatrutide's glucagon receptor agonism distinguishes it from semaglutide and tirzepatide. Glucagon promotes hepatic glucose output and also stimulates amino acid catabolism in the liver. Some animal data suggest that glucagon signaling may influence one-carbon metabolism through effects on methionine cycle intermediates, though this has not been demonstrated in human trials at clinical doses [11]. This is an area of active investigation. Until human data clarify the relationship, glucagon receptor agonism should not be used as a reason to adjust folate dosing beyond standard evidence-based recommendations.

Practical Co-Administration Instructions

Timing is straightforward. Retatrutide is injected once weekly, subcutaneously, typically in the abdomen, thigh, or upper arm. Folate is taken orally once daily. There is no pharmacokinetic reason to separate the two in time; the routes of administration, receptor targets, and elimination pathways do not overlap.

Supplement Form Comparison

| Form | Bioavailability | Best For | |---|---|---| | Folic acid | ~85% with food | General adult population | | L-methylfolate (5-MTHF) | High; bypasses MTHFR | MTHFR C677T homozygotes, metformin users | | Folinic acid (leucovorin) | High | Anticonvulsant users needing high doses | | Food-derived folate | Variable (50 to 80%) | Adequate diet, low-risk patients |

Minimizing Nausea-Related Non-Adherence

Take folate with the largest meal of the day to reduce GI side effects from both the supplement and retatrutide-induced nausea. If nausea from retatrutide is severe during dose escalation, a liquid or chewable folate formulation may be better tolerated than a standard tablet.

What the Phase 2 Retatrutide Trial Does and Does Not Tell Us About Nutrition

The 2023 NEJM Phase 2 trial (NCT05019261) did not report micronutrient outcomes. The primary endpoint was percent change in body weight at 24 weeks; secondary endpoints included glycemic markers, lipids, and blood pressure [1]. This gap is common in early GLP-1-class trials. For context, a 2022 bariatric surgery outcomes review in JAMA Surgery found that approximately 35 to 50% of Roux-en-Y gastric bypass patients developed folate deficiency within 12 months if not supplemented [12]. While retatrutide is not surgery and does not alter GI anatomy, the dietary restriction it induces may be comparable in magnitude to surgical restriction over time, warranting similar nutritional vigilance.

The SURMOUNT-4 trial of tirzepatide (a dual GIP/GLP-1 agonist structurally related to retatrutide) also did not report micronutrient endpoints despite producing 25.8% mean weight loss over 88 weeks [13]. The absence of data is not evidence of safety; it reflects a gap in trial design that post-market studies and registry data will need to fill.

Patients and clinicians should not interpret the lack of folate-interaction warnings in retatrutide prescribing materials as evidence that nutritional monitoring is unnecessary. The drug is investigational, prescribing data are sparse, and nutritional depletion events may not be captured in Phase 2 sample sizes.

Key Takeaways for Clinicians Prescribing Retatrutide

Standard folate supplementation (400 to 800 mcg/day) requires no modification solely because a patient is taking retatrutide. The interaction risk is indirect, driven by caloric restriction, nausea-related non-adherence, or co-medications rather than any receptor-level competition. Patients in high-risk subgroups, including MTHFR variant carriers, metformin co-users, anticonvulsant users, and women of childbearing potential, need individualized folate dosing and periodic lab monitoring. Screen all retatrutide patients for baseline folate and homocysteine status, and repeat at 3 months during the peak nausea and dose-escalation phase. If RBC folate falls below 3 ng/mL at any point during therapy, escalate supplementation immediately and identify the cause.